| Bioactivity | Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody[1]. |
| Target | Influenza B virus |
| Invitro | Lesofavumab (MHAB5553A) 与血凝素 (HA) 残留酯酶结构域的一个保守表位结合，血凝素是 B 型流感病毒上的一种主要免疫显性表面糖蛋白，并在内体中阻断 HA 介导的膜融合[1]。Lesofavumab (46B8) 能够中和所有 11 种与 >70 年人类感染相关的 IBV 菌株，IC50 值范围为 0.58-0.95 nM[2]。Lesofavumab (46B8; 0-100 ng/mL) 在体外阻断膜融合并诱导抗体依赖性细胞毒性 (ADCC)[2]。 |
| In Vivo | Lesofavumab (46B8; 15 mg/kg; i.v.; single dose) 能够保护小鼠免受突变型 B 型流感病毒的致命性[2]。 Animal Model: |
| Name | Lesofavumab |
| CAS | 1807960-57-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Rao GK, et al. In Vivo Assessment of Antibody-Dependent Enhancement of Influenza B Infection. Toxicol Sci. 2019 Jun 1;169(2):409-421. [2]. Chai N, et al. A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action. Nat Commun. 2017 Jan 19;8:14234. |